Latest Novaremed News & Updates

See the latest news and media coverage for Novaremed. We track all announcements, press releases, and industry mentions in real time, all in one place.

Novaremed

Clinical-stage biopharmaceutical company developing non-opioid pain therapies

novaremed.com

Headquarters: Basel, Switzerland
Founded year: 2017
Company type: Private company
Number of employees: 5–10

Last updated Today

Latest news about Novaremed

Company announcements

2 September 2025 Novaremed

Novaremed completes patient visits in Phase 2b trial

The NIH-funded trial evaluates nispomeben for chronic pain in diabetic peripheral neuropathy. Topline results expected November 2025.

7 May 2025 Novaremed

Novaremed completes enrollment in Phase 2b study of NRD.E1

The NIH-sponsored trial enrolled 127 patients for non-opioid treatment of diabetic peripheral neuropathy pain. Topline data expected in Q4 2025.

31 January 2023 Novaremed

Novaremed announces publication of MP-101 pharmacological profile

MP-101, in Phase 2 for preventing chemotherapy-induced peripheral neuropathy, shows superior potency in animal models of pain, cognition, and depression.

21 July 2022 Novaremed

Novaremed enters license agreement with NeuroFront for NRD.E1

NeuroFront gains option for exclusive rights in Greater China and Singapore. Novaremed receives over USD 130 million in fees, milestones, and royalties.

Media coverage

2 September 2025 BioSpace

Novaremed Announces Completion of All Patient Visits in NIH-Funded Phase 2b Trial of Non-Opioid Nispomeben for Treating Chronic Pain Associated with Diabetic Peripheral Neuropathy - BioSpace

Basel, Switzerland, 2 September 2025 – Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces completion of the last patient last visit (LPLV) in the...

6 May 2025 Yahoo Finance

Novaremed Announces Completion of All Patient Visits in NIH-Funded Phase 2b Trial of Non-Opioid Nispomeben for Treating Chronic Pain Associated with Diabetic Peripheral Neuropathy

Last patient last visit (LPLV) was reached for the 127 adult and elderly patients enrolled into the 12-week placebo-controlled trial with nispomeben (NRD.E1) Topline results...

21 July 2022 Business Wire

Novaremed signs an exclusive option and license agreement with NeuroFront for the non-opioid neuropathic pain treatment, NRD.E1, for Greater China and Singapore

Novaremed AG and NeuroFront Therapeutics (Hong Kong) Limited have jointly announced the signing of an exclusive collaboration and commercialization agreement for...

17 March 2022 FinanzNachrichten

Novaremed AG: The non-opioid lead compound NRD.E1 from Novaremed is being tested in a Phase-2 study of the NIH-HEAL Initiative for the treatment of chronic pain

Novaremed AG, a biopharma private company active in the field of clinical research, announces a study in collaboration with the National Institutes of Health (NIH), in which...

Never miss news about Novaremed

Track Novaremed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.